ExploraMed, a US-based medical tech incubator, accelerates the creation of innovative medical devices, meeting global health needs.
Founded in Mountain View, United States, ExploraMed NC7 is a venture-backed medical technology incubation company. Its core mission is to accelerate the creation and establishment of innovative medical devices that address persistent global health challenges. The company leverages substantial financial and intellectual resources to develop new medical technologies, procedures, and businesses. ExploraMed focuses on identifying and nurturing medical devices that meet key fundamental criteria, aiming to bring impactful solutions to market.
Notable affiliated individuals include experienced entrepreneurs and medical professionals who contribute their expertise to the development process. The company has garnered significant investment from leading venture capital firms, enhancing its capacity to innovate. Key achievements include the successful incubation and commercialization of several groundbreaking medical devices that have improved patient outcomes. Overall, ExploraMed has made a substantial impact on the medical technology landscape by fostering advancements that address critical healthcare needs.

Foundry
thefoundry.com

Denali Medical
denalimedical.com

Medtech Innovator

Shifamed
shifamed.com

Proa Medical
proamedical.com

Nuveta
nuveta.com

Ontogen Medtech
ontogenmedtech.com

Medicreations
medicreations.com
Optivia

MedTech Venture Partners
medtechvp.com
Prospex Medical

Kapstone Medical
uLink Labs
ulink-labs.com

Medtor
medtorllc.com
Inceptus Medical
Companies similar to ExploraMed NC7 include Foundry, Denali Medical, Medtech Innovator and Shifamed.
ExploraMed NC7 was founded in 2014.
ExploraMed NC7's headquarters is located in Mountain View, CA, US.
ExploraMed NC7's most recent funding round was for $32.5M (USD) in October 2020.
As of Oct 1, 2020, ExploraMed NC7 has disclosed funding of $132.6M (USD). Undisclosed round amounts are excluded.
ExploraMed NC7 has 30 employees as of Feb 4, 2024.